The European Medicines Agency or EMA said Friday that it has recommended the approval of Eurartesim, from Sigma-tau Industrie Farmaceutiche Riunite SpA, a fixed combination product consisting of dihydroartemisinin and piperaquine phosphate, for the treatment of uncomplicated Plasmodium falciparum malaria.
EMA recommends approval of Eurartesim for uncomplicated malaria